Meridien Research   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Tampa FL United States (2000)

Organization Overview

First Clinical Trial
2005
NCT00293657
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Meridian Clinical Research | Meridian Clinical Research, Bellevue, NE 68005 | Meridian Clinical Research, Omaha (NE), USA | Meridian Clinical Research, Savannah (GA), USA | Meridien Research, Brooksville, FL 34601 | Meridien Research Inc. | Meridien Research - Tampa

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Atrophic Vaginitis (Phase 3)

Atrophy (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Communicable Diseases (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Disease (Phase 3)

Headache (Phase 2)

Hot Flashes (Phase 3)

Hyperkinesis (Phase 3)

Hypertriglyceridemia (Phase 2)

Infections (Phase 2)

Influenza, Human (Phase 3)

Migraine Disorders (Phase 2)

Osteoarthritis (Phase 3)

Respiratory Tract Diseases (Phase 2)

Respiratory Tract Infections (Phase 2)

RNA Virus Infections (Phase 2)

Vaginitis (Phase 3)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 24